Showing results (181-190 of 191) with videos related to
Sort By:
Pageof 20
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|September 28, 2011
Chagas disease in European countries: the challenge of a surveillance systemL Basile, J M Jansa, Y Carlier, et al.Plos One|July 18, 2022
Alterations in the molecular composition of COVID-19 patient urine, detected using Raman spectroscopic/computational analysisJohn L Robertson, Ryan S Senger, Janine Talty, et al.JAMA Network Open|July 5, 2023
Perspectives About Racism and Patient-Clinician Communication Among Black Adults With Serious IllnessCrystal E Brown, Arisa R Marshall, Cyndy R Snyder, et al.Journal of Medicinal Chemistry|July 26, 2002
Selective alpha4beta7 integrin antagonists and their potential as antiinflammatory agentsNathan J P Dubree, Dean R Artis, Georgette Castanedo, et al.Bioorganic & Medicinal Chemistry Letters|September 25, 2002
Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophoresGeorgette M Castanedo, Fredrick C Sailes, Nathan J P Dubree, et al.Journal of Medicinal Chemistry|October 28, 1997
Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agentsD Y Jackson, C Quan, D R Artis, et al.Blood Cancer Journal|May 30, 2015
A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignanciesS Y Kim, J-W Theunissen, J Balibalos, et al.Molecular Pharmaceutics|September 23, 2015
Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCsChristopher R Behrens, Edward H Ha, Lawrence L Chinn, et al.Nature Cancer|February 5, 2022
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunityShelley E Ackerman, Cecelia I Pearson, Joshua D Gregorio, et al.Pageof 20